IN2014MN00191A - - Google Patents

Info

Publication number
IN2014MN00191A
IN2014MN00191A IN191MUN2014A IN2014MN00191A IN 2014MN00191 A IN2014MN00191 A IN 2014MN00191A IN 191MUN2014 A IN191MUN2014 A IN 191MUN2014A IN 2014MN00191 A IN2014MN00191 A IN 2014MN00191A
Authority
IN
India
Application number
Inventor
Chafiq Hamdouchi
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46690732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014MN00191(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IN2014MN00191A publication Critical patent/IN2014MN00191A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN191MUN2014 2011-08-17 2014-01-30 IN2014MN00191A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161524462P 2011-08-17 2011-08-17
PCT/US2012/050051 WO2013025424A1 (en) 2011-08-17 2012-08-09 A Novel 1,2,3,4-Tetrahydroquinoline Derivative Useful for the Treatment of Diabetes

Publications (1)

Publication Number Publication Date
IN2014MN00191A true IN2014MN00191A (en) 2015-08-21

Family

ID=46690732

Family Applications (1)

Application Number Title Priority Date Filing Date
IN191MUN2014 IN2014MN00191A (en) 2011-08-17 2014-01-30

Country Status (30)

Country Link
US (1) US8431706B2 (en)
EP (1) EP2744806B1 (en)
JP (1) JP5903162B2 (en)
KR (1) KR101570624B1 (en)
CN (1) CN103687856B (en)
AP (1) AP3589A (en)
AR (1) AR087451A1 (en)
AU (1) AU2012295372A1 (en)
BR (1) BR112014003079A2 (en)
CA (1) CA2843474C (en)
CL (1) CL2014000357A1 (en)
CO (1) CO6880069A2 (en)
CR (1) CR20140052A (en)
DO (1) DOP2014000018A (en)
EA (1) EA022165B1 (en)
EC (1) ECSP14013211A (en)
ES (1) ES2578165T3 (en)
GT (1) GT201400022A (en)
IL (1) IL230635A (en)
IN (1) IN2014MN00191A (en)
MA (1) MA35351B1 (en)
MX (1) MX2014001832A (en)
PE (1) PE20140831A1 (en)
PH (1) PH12014500366A1 (en)
SG (1) SG11201401793PA (en)
TN (1) TN2014000058A1 (en)
TW (1) TWI537262B (en)
UA (1) UA110983C2 (en)
WO (1) WO2013025424A1 (en)
ZA (1) ZA201400705B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014372114A1 (en) 2013-11-14 2016-06-09 Cadila Healthcare Limited Novel heterocyclic compounds
US9957219B2 (en) 2013-12-04 2018-05-01 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
EP3102198B1 (en) 2014-02-06 2020-08-26 Merck Sharp & Dohme Corp. Antidiabetic compounds
CN109666027A (en) * 2017-10-17 2019-04-23 中国科学院上海药物研究所 GPR40 agonist compound of a kind of amide structure and application thereof
MX2020007283A (en) 2018-01-08 2020-09-10 Celon Pharma Sa 3-phenyl-4-hexynoic acid derivatives as gpr40 agonists.
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2019204609A1 (en) 2018-04-19 2019-10-24 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
BR112020026746A2 (en) 2018-07-13 2021-03-30 Gilead Sciences, Inc. COMPOUND, PHARMACEUTICAL COMPOSITION, METHODS TO INHIBIT PD-1, PD-L1 AND / OR THE INTERACTION OF PD-1 / PD-L1 AND TO TREAT CANCER, AND, KIT TO TREAT OR PREVENT CANCER OR A DISEASE OR CONDITION.
CN112955435B (en) 2018-10-24 2024-09-06 吉利德科学公司 PD-1/PD-L1 inhibitors
CN113906015B (en) 2019-05-31 2024-03-01 现代药品株式会社 New crystal form of 3-(4-(benzyloxy)phenyl)hex-4-ynoic acid derivatives
TWI751585B (en) * 2019-06-28 2022-01-01 美商美國禮來大藥廠 Glucagon-like peptide 1 receptor agonists
JP2022552655A (en) 2019-10-07 2022-12-19 キャリーオペ,インク. GPR119 agonist
EP4052790A4 (en) * 2019-10-31 2023-12-27 China Petroleum & Chemical Corporation SUPPORTED CATALYST, PRODUCTION PROCESS THEREOF AND APPLICATION THEREOF
PH12022552277A1 (en) 2020-02-28 2024-03-04 Kallyope Inc Gpr40 agonists
JP2023526625A (en) 2020-05-19 2023-06-22 キャリーオペ,インク. AMPK Activator
CN116390925A (en) 2020-06-26 2023-07-04 卡尔优普公司 AMPK activator
KR102699076B1 (en) * 2021-04-01 2024-08-27 현대약품 주식회사 Novel use of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative
CN115317484B (en) * 2022-08-26 2023-07-18 北京箭牧科技有限公司 Application of LY2922470 in preparing medicine for preventing or treating cerebrovascular diseases or tissue ischemia reperfusion injury
CN115671105B (en) * 2022-11-22 2023-10-27 北京箭牧科技有限公司 Application of LY2922470 in preparation of medicines for preventing or treating kidney diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199900147A (en) * 1998-09-17 1999-09-06 1, 2, 3, 4- TETRAHIDROQUINOLINAS 2-SUBSTITUTED 4-AMINO SUBSTITUTED.
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
DE60205234T2 (en) * 2001-03-27 2006-05-24 Actelion Pharmaceuticals Ltd. 1,2,3,4-TETRAHYDROISOCHINOLINE DERIVATIVES AS UROTENSIN II RECEPTOR ANTAGONISTS
EA011010B1 (en) * 2004-02-27 2008-12-30 Эмджен, Инк. Compounds modulating of gpr40 receptor, pharmaceutical composition, method for treating diseases responsive to the modulation of gpr40 receptor (embodiments), method for modulating gpr40 function (embodiments) and method for modulating circulating insulin concentration
EP1726580A4 (en) * 2004-03-15 2008-02-13 Takeda Pharmaceutical AMINOPHENYLPROPANSÄUREDERIVAT
EP1731505B1 (en) * 2004-03-30 2015-01-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
AR078522A1 (en) * 2009-10-15 2011-11-16 Lilly Co Eli SPIROPIPERIDINE COMPOUND, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT DIABETES AND INTERMEDIARY COMPOUND FOR SYNTHESIS
AR078948A1 (en) * 2009-11-30 2011-12-14 Lilly Co Eli SPYROPIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION THAT INCLUDE IT AND ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT DIABETES

Also Published As

Publication number Publication date
TWI537262B (en) 2016-06-11
CR20140052A (en) 2014-06-20
SG11201401793PA (en) 2014-09-26
BR112014003079A2 (en) 2017-02-21
EP2744806B1 (en) 2016-04-27
EP2744806A1 (en) 2014-06-25
CA2843474C (en) 2015-12-15
UA110983C2 (en) 2016-03-10
WO2013025424A1 (en) 2013-02-21
JP2014521744A (en) 2014-08-28
ECSP14013211A (en) 2014-03-31
CN103687856A (en) 2014-03-26
ES2578165T3 (en) 2016-07-21
EA022165B1 (en) 2015-11-30
KR20140041835A (en) 2014-04-04
IL230635A (en) 2015-11-30
TN2014000058A1 (en) 2015-07-01
DOP2014000018A (en) 2014-04-15
US8431706B2 (en) 2013-04-30
TW201319060A (en) 2013-05-16
KR101570624B1 (en) 2015-11-19
AP2014007436A0 (en) 2014-02-28
AU2012295372A1 (en) 2014-01-23
US20130045990A1 (en) 2013-02-21
PH12014500366A1 (en) 2014-04-14
CN103687856B (en) 2015-07-22
PE20140831A1 (en) 2014-07-14
AP3589A (en) 2016-02-15
MA35351B1 (en) 2014-08-01
ZA201400705B (en) 2015-11-25
MX2014001832A (en) 2014-02-27
JP5903162B2 (en) 2016-04-13
CL2014000357A1 (en) 2014-09-05
CO6880069A2 (en) 2014-02-28
GT201400022A (en) 2015-01-16
CA2843474A1 (en) 2013-02-21
NZ621248A (en) 2015-08-28
IL230635A0 (en) 2014-03-31
EA201490269A1 (en) 2014-05-30
AR087451A1 (en) 2014-03-26

Similar Documents

Publication Publication Date Title
BR112013022641A2 (en)
BR112013031251A2 (en)
BR112013023185A2 (en)
BR112013022995A2 (en)
BR112013017670A2 (en)
BR112013027830A2 (en)
AP3853A (en)
BR112013024365A2 (en)
BR112013028733A2 (en)
AP2016009466A0 (en)
BR112013031556A2 (en)
BR112013032368A2 (en)
BR112013032380A2 (en)
BR112013032377A2 (en)
BR112013027836A2 (en)
BR112013018949A2 (en)
BR112013027761A2 (en)
IN2014MN00191A (en)
BR112013021637A2 (en)
BR112013032392A2 (en)
BR112013017878A2 (en)
BR112013030734A2 (en)
BR112013027871A2 (en)
BR112013032394A2 (en)
BR112013022499A2 (en)